Anavex names Terrie Kellmeyer permanent CEO and board member

Anavex Life Sciences Corp. (NASDAQ: AVXL) announced that its board of directors appointed Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer on November 1, 2026. She will also join the company's board of directors.

Kellmeyer had been serving as Interim Chief Executive Officer and Senior Vice President of Clinical Development at Anavex. The appointment makes her role permanent following her interim tenure.

Kellmeyer holds a Ph.D. in Molecular Biology from SUNY Syracuse and completed a postdoctoral fellowship at the University of Rochester. She has more than 30 years of biopharmaceutical industry experience in clinical development, regulatory affairs, clinical operations and medical affairs. She previously held senior leadership positions at Aardvark Therapeutics, Acer Therapeutics, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Amylin Pharmaceuticals and Gen-Probe.

During her interim leadership, Anavex reported completing key clinical pharmacology studies, receiving FDA clearance of an Investigational New Drug application in Fragile X syndrome, and advancing its planned Phase 3 Rett syndrome program.

Anavex is developing blarcamesine (ANAVEX 2-73) for Alzheimer's disease, Rett syndrome and Fragile X syndrome.

"My priorities are clear: disciplined execution of our clinical plans, generating high-quality data to support regulatory decisions and transparent communication with patients, investors and regulators," Kellmeyer said in a statement.

You May Also Be Interested In

• Teads names Michael Coyle as CFO, replacing 13-year veteran
• Edgewise gets FDA backing for EDG-7500 Phase 3 HCM trial design
• Nemi Corp. to go public via SPAC deal at $400M valuation